|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-3-3
|
|
pubmed:abstractText |
To assess safety and tolerability, we administered valacyclovir, an oral anti-viral medication that inhibits erythrocyte sickling in vitro, to 14 subjects with sickle-cell anemia for 1 week at a standard dose of 1,000 mg every 8 hr. No clinically significant adverse effects occurred. In 11 subjects in steady state, the mean hemoglobin concentration was almost constant while the absolute reticulocyte count decreased in eight (P = 0.1) and the overall mean fell slightly although not significantly (10%, P = 0.2). These results suggest that valacyclovir is safe and well tolerated in patients with sickle-cell anemia and that a longer duration of therapy merits investigation.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
843-5
|
|
pubmed:meshHeading |
pubmed-meshheading:21370420-Acyclovir,
pubmed-meshheading:21370420-Adolescent,
pubmed-meshheading:21370420-Adult,
pubmed-meshheading:21370420-Anemia, Sickle Cell,
pubmed-meshheading:21370420-Antisickling Agents,
pubmed-meshheading:21370420-Antiviral Agents,
pubmed-meshheading:21370420-Erythrocytes, Abnormal,
pubmed-meshheading:21370420-Female,
pubmed-meshheading:21370420-Hemoglobins,
pubmed-meshheading:21370420-Humans,
pubmed-meshheading:21370420-Male,
pubmed-meshheading:21370420-Maximum Tolerated Dose,
pubmed-meshheading:21370420-Prodrugs,
pubmed-meshheading:21370420-Prospective Studies,
pubmed-meshheading:21370420-Safety,
pubmed-meshheading:21370420-Survival Rate,
pubmed-meshheading:21370420-Treatment Outcome,
pubmed-meshheading:21370420-Valine,
pubmed-meshheading:21370420-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Safety of short-term valacyclovir as an anti-sickling agent in sickle-cell anemia.
|
|
pubmed:affiliation |
Division of Pediatric Hematology, Columbia University Medical Center, New York, New York, USA. ke2144@columbia.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
